Alexandra Griessbach, Frédérique Chammartin, Irene A Abela, Patrizia Amico, Marcel P Stoeckle, Anna L Eichenberger, Barbara Hasse, Dominique L Braun, Macé M Schuurmans, Thomas F Müller, Michael Tamm, Annette Audigé, Nicolas J Mueller, Andri Rauch, Huldrych F Günthard, Michael T Koller, Alexandra Trkola, Selina Epp, Alain Amstutz, Christof M Schönenberger, Ala Taji Heravi, Matthaios Papadimitriou-Olivgeris, Alessio Casutt, Oriol Manuel, Katharina Kusejko, Heiner C Bucher, Matthias Briel, Benjamin Speich
BACKGROUND: After basic immunization with 2 mRNA SARS-CoV-2 vaccine doses, only a small proportion of patients who are severely immunocompromised generate a sufficient antibody response. Hence, we assessed the additional benefit of a third SARS-CoV-2 vaccine in patients with different levels of immunosuppression. METHODS: In this observational extension of the COVERALL trial (Corona Vaccine Trial Platform), we recruited patients from the Swiss HIV Cohort Study and the Swiss Transplant Cohort Study (ie, lung and kidney transplant recipients)...
November 2023: Open Forum Infectious Diseases